Some groups have also failed to observe sufficient depletion of Treg cells using iterative dosing regimens in patients with metastatic melanoma.66, 67, 68 In spite of these, improved anti‐tumour immune responses were reported.66 A study of 300 mg/m2 CY in ovarian cancer found neither a quantitative reduction nor qualitative difference in CD4+ Foxp3+ Treg cell function.69 Despite this, patients receiving CY had enhanced vaccine‐induced anti‐tumour Th1 effector responses, so displaying differential effects on potentiating vaccine immunogenicity. The gene discussed is FOXP3; the disease is neoplasm.